The Business Case for Cardiac AI Diagnostics: What It Actually Takes to Build and Ship

This is the strategic companion to our piece on Cardiac AI Diagnostics: The Engineering Behind ECG Interpretation at Clinical Grade. If you’re a CEO, head of product, or founder scoping a cardiac AI program,  markets, build/buy/partner, regulatory cost, timeline, start here. If you’re the engineering or clinical lead figuring out what “clinical grade” actually requires, the technical companion is for you.

Cardiac AI is one of the few clinical AI categories where the technology is mature, the clinical use cases are well-defined, the regulatory pathway is established, and meaningful product-market fit has been demonstrated. It’s also a category where most programs fail, not on the model, but on data acquisition, regulatory burden, clinical adoption, or reimbursement.
This article is about the business reality, drawn from building KARDI AI’s cardiac diagnostic from concept to CE-marked Class IIa device.

Why Cardiac AI Is a Real Market, Right Now

ECG interpretation is the highest-volume diagnostic test in medicine. Most ECGs are interpreted by non-cardiologists, emergency physicians, internists, GPs, nurses, and most of those interpretations could be improved by software-assisted triage. The clinical value of catching STEMI faster, surfacing atrial fibrillation earlier, and reducing missed conduction abnormalities is well-established, with measurable impact on patient outcomes.

The market structure has three durable demand drivers: clinician shortage (especially in cardiology and emergency medicine), volume growth (aging populations, expanded screening), and the formalisation of AI-assisted reading as a recognised standard of care in major guidelines.

What this means commercially: cardiac AI buyers exist, the budget exists, and the clinical value proposition doesn’t need to be invented. The competitive question is whether your specific product wins, not whether the category is real.

The category isn’t greenfield. Multiple CE-marked and FDA-cleared cardiac AI products are on the market. Hospital systems have begun standardising on platforms. New entrants need to differentiate on a defensible vector. Typically condition coverage, integration depth, performance on rare-but-critical conditions, or workflow fit, rather than competing on baseline accuracy alone.

Where the Value Concentrates

Three product shapes dominate cardiac AI commercially.

Triage and prioritisation in clinical workflow. AI flags high-acuity findings (STEMI, life-threatening arrhythmias) for immediate clinician review and deprioritises normal recordings. The buyer is a hospital or hospital network. The value is throughput and missed-diagnosis reduction. Sales cycles are long (12–24 months), deal sizes are meaningful, and stickiness is high once integrated.

Decision support at point of care. AI provides a real-time interpretation alongside the cardiologist’s read, used as a second opinion or to surface findings the human might have missed. Sold to hospitals and increasingly to ambulatory cardiology practices. Smaller deal sizes but higher volume, and direct workflow integration with existing ECG carts is the technical requirement.

Screening at scale (primary care, occupational health, remote care). AI interprets ECGs in non-specialist settings, flagging cases that need referral. Buyers include payors, large primary care networks, telehealth platforms, and corporate wellness programs. This is where wearable-class single-lead products dominate, not 12-lead systems.

The strategic question for a new entrant: which shape does your product serve, and is your data, model, and clinical evidence aligned with that shape? Cardiac AI products that try to serve all three usually serve none well.

The Real Strategic Question: Data Moat

Algorithm quality matters less than most teams believe, and data moat matters more.

The published research on ECG model architectures has converged. Two teams with similar engineering capability and similar architectures will produce models with similar benchmark performance. The differentiator is data: how many ECGs, from how many equipment vendors, across how many clinical settings, with what label quality.

Building KARDI AI required hundreds of thousands of proprietary ECGs from clinical partners across multiple vendors and care contexts. That dataset is the product as much as the model is. And it’s the asset that’s hardest to replicate. Clinical data partnerships take years to form, require institutional trust, and depend on reciprocal value to the partner.

Three strategic implications follow. Time-to-data is the gating constraint, not time-to-model: a team with strong engineering and weak clinical relationships will produce a worse product than a team with average engineering and strong clinical relationships, every time. The first 18 months of a cardiac AI program should be disproportionately invested in clinical data partnerships, IRB-approved data acquisition, and labelling infrastructure — companies that under-invest here ship a model that benchmarks well and degrades in the field. And public datasets are useful for prototyping, infeasible as a basis for a CE-marked product. Treat them as scaffolding, not foundation.

This is also why “buy a cardiac AI startup” is a more common path than “build cardiac AI inside a med tech incumbent.” The data and clinical relationships are difficult to bootstrap inside a hardware-led organisation; acquisition gets you there faster than internal build.

Build vs. Buy vs. Partner

Med tech companies looking at cardiac AI fall into three categories.

Build internally. Realistic when the company already owns the ECG hardware platform and has clinical data flowing from existing deployments. The hardware-software integration becomes a moat. The risk is that internal ML capability is rarely strong enough on day one, and hiring is slow. Realistic timeline from start to CE mark: 36–48 months. Realistic spend: €15–30M+ depending on data acquisition strategy and headcount.

Acquire. The fastest path for a hardware-led med tech company that wants to add AI to a platform. The pay-up is significant — successful cardiac AI startups with CE-marked products and clinical traction trade at strategic premiums — but acquisition compresses time-to-market by 24+ months. Integration risk is the largest hidden cost.

Partner. OEM-style licensing, where a med tech company embeds a third-party AI vendor’s diagnostic in its hardware platform. Lowest upfront commitment, fastest time to market, weakest defensibility. The vendor has the data, the regulatory file, and the option to switch hardware partners. Useful for fast-follower commercial coverage; weak as a long-term strategic position.

The right answer depends on whether AI is a feature of your platform or a strategic asset. Most med tech incumbents who treated AI as a feature in 2020–22 are now treating it as strategic, and discovering they should have started building the data moat earlier.

Timeline and Cost Reality

Realistic numbers for a cardiac AI program targeting CE mark and US clearance in parallel, starting from zero:

Months 0–9 cover data acquisition partnerships, IRB approvals, and labelling pipeline setup. Headcount runs 4–6 (clinical lead, ML lead, data engineer, regulatory lead, 1–2 ML engineers). Spend in this window: €1.5–3M.

Months 9–24 cover model development, preprocessing pipeline, internal validation, and multi-site validation. Headcount expands to 8–12. Spend in this window: €4–8M.

Months 24–36 cover regulatory documentation, clinical evaluation, usability evaluation, notified body submission, and response to questions. Spend in this window: €3–5M plus €0.5–1M in regulatory and notified body fees.

Months 36–42 cover CE mark, market launch, post-market surveillance setup, and FDA submission running in parallel through the back half. Spend: €2–4M including go-to-market.

Total to CE mark: 36–42 months, €10–20M, for a company starting from zero. Faster and cheaper if a related platform exists to amortise against; slower and more expensive if data partnerships are weak or regulatory is under-resourced.

The most common timeline assassin is under-budgeting the regulatory documentation phase. Teams routinely spend 80% of their effort on the model and discover they have six months of regulatory writing they hadn’t planned for. Budget regulatory at roughly 25% of total program effort.

The most common cost assassin is poor data strategy. Teams that over-rely on public data spend the savings ten times over on degraded clinical performance and the resulting validation failures.

The Clinical Adoption Problem (Where Most Products Stall)

Approval is not adoption. A CE-marked, FDA-cleared cardiac AI that achieves 95% accuracy on its validation set can still fail commercially because of three adoption problems.

Alert fatigue. False positives erode clinician trust faster than false negatives. A system that flags too aggressively gets ignored within weeks. Once clinicians learn to dismiss alerts, the product is dead in that institution. Calibration and threshold strategy isn’t an engineering nicety. Iit’s a commercial question.

Workflow friction. Cardiac AI that requires clinicians to log into a separate system, change their reading workflow, or fight with the EMR is rejected at adoption. The technical integration with ECG carts, PACS, and EMRs determines commercial outcomes more than model accuracy. Sales cycles often hinge on whether IT integration takes weeks or months.

Trust building. Clinicians need to understand why the model flagged what it flagged. Models that produce attention maps or explainable outputs get adopted faster than opaque models, even at slightly lower benchmark accuracy. This is not a regulatory point; it’s a commercial one. Clinicians who can’t see the model’s reasoning don’t change their behaviour based on it.

The implication: clinical product management, the work of fitting AI into existing clinical workflows in a way clinicians actually use, is the second-most-underinvested capability in cardiac AI startups, after data partnerships. Companies that resource this seriously ship faster from approval to revenue.

Reimbursement: The Question Most Programs Avoid Until It’s Too Late

CE mark and FDA clearance let you sell. Reimbursement determines whether anyone buys at scale.

The reimbursement landscape for AI-assisted ECG interpretation is heterogeneous and evolving. In the EU, reimbursement is country-by-country and largely buried in existing diagnostic codes; hospitals pay from operational budgets, and direct AI reimbursement codes are rare and emerging. In the US, the CMS NTAP (New Technology Add-on Payment) and dedicated CPT codes for AI-assisted diagnostics are slowly expanding. Cardiac AI products with documented outcomes data have a real path; products without it don’t.

A cardiac AI go-to-market plan without an explicit reimbursement strategy is a plan to sell into hospital operational budgets indefinitely, which works at small scale and breaks at large scale. Programs that build outcomes evidence into clinical evaluation from day one position themselves for reimbursement five years later. Programs that don’t, can’t.

Long-Term Defensibility

What does a defensible cardiac AI product look like in 2030? Five things compound.

Data scale and breadth that competitors can’t replicate without 3+ years of clinical partnership work. Continuously updated models under a PCCP framework, where each retraining cycle compounds the data advantage instead of triggering a fresh regulatory submission. Deep workflow integration with installed ECG hardware bases that creates switching costs. Outcomes evidence linking AI-assisted reads to measurable patient benefit — the only evidence that ultimately drives reimbursement, payer adoption, and durable clinical preference. Brand and clinical relationships that make your product the default in a category (cardiology departments, emergency medicine residencies, cardiology fellowship training).

Models alone are not durable competitive advantages in cardiac AI. The ML capability has commoditised. The data, the regulatory posture, the clinical integration, and the outcomes evidence are what compound over time.

Where the AI Act and PCCP Change the Calculus

Two regulatory shifts are reshaping the cardiac AI business case.

The EU AI Act adds a layer of compliance on top of MDR for high-risk AI systems including cardiac diagnostics. Programs targeting 2026+ EU launch face documentation and governance requirements that didn’t exist for first-generation cardiac AI products. The cost is real; the strategic implication is that incumbents already through MDR have a cost advantage over new entrants who must clear both regimes simultaneously.

FDA’s Predetermined Change Control Plan (PCCP) framework, formalised in 2024, lets companies pre-authorise specific kinds of model updates. For cardiac AI programs planning ongoing improvement post-launch, a PCCP can dramatically reduce the lifetime regulatory cost. The strategic implication: PCCP is now a competitive lever, not just a compliance feature. A company shipping monthly model improvements within a PCCP envelope outpaces a competitor that ships annually with full re-submissions.

Both shifts favour programs that treat regulatory strategy as a core competence from the start — and disadvantage programs that bolt it on late.

What We’d Do Differently With Hindsight

A summary of what we learned building KARDI AI, in order of impact:

Spend more on clinical data partnerships and label quality in months 0–12. Everything downstream gets easier when this is right.

Resource regulatory writing in parallel with model development, not after it. Treat the technical file as the product, because in regulatory terms it is.

Build the post-market monitoring infrastructure before launch, not after. Retrofitting it costs more than building it properly.

Plan PCCP scope before submission. The cost of going back to redefine the change envelope after a CE mark is significant.

Invest seriously in clinical product management — the workflow integration work that determines whether the product is actually used after it’s bought.

Build an explicit reimbursement strategy in year one. Outcomes data needs to be designed into the clinical evaluation from the beginning, not assembled retroactively.

Where Vector Labs Fits

We work with med tech companies on cardiac AI programs at three points: scoping (build/buy/partner decisions and program design), technical due diligence (assessing in-flight programs or acquisition targets), and engineering execution (data infrastructure, ML pipelines, regulatory documentation support).

If you’re scoping a cardiac AI program, internally or as an acquisition, and want to pressure-test the plan against what we learned building a CE-marked Class IIa cardiac diagnostic, get in touch at vector-labs.ai.

For the engineering reality behind this strategic view — model architectures, preprocessing, validation, labelling, calibration, and the regulatory technical file — the companion technical article is here.